p-menthane-3,8-diol oil

Small molecule

RRoyal North Shore Hospital

p-menthane-3,8-diol oil is one of 10 small molecule programs targeting Impetigo. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImpetigoActive, not recruiting

ImpetigoPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Impetigo

#DrugCompanyPhaseTrials

Minocin

Zyvox

1 3

Bactroban

PPadagis LLC

Phase 3

1 4

Fucidin

LEO Pharma

Approved

1 5

Xepi

LLnhc

Phase 3

2 6

Atx201

UUNION therapeutics

Phase 2

1 7

Topical Minocycline Foam FXFM244

VVyne Therapeutics Inc.

Phase 2

1 8

NVC-422

NNovaBay Pharmaceuticals, Inc.

Phase 2

1 9

LTX-109

LLytix Biopharma AS

Phase 2

1 10

p-menthane-3,8-diol oil

RRoyal North Shore Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Impetigo1 trial

Citriodiol® and Impetigo

Unknown status·RRoyal North Shore Hospital·Phase 2/3·NCT01611909·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for p-menthane-3,8-diol oil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — p-menthane-3,8-diol oil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for p-menthane-3,8-diol oil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Royal North Shore Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: RRoyal North Shore Hospital

p-menthane-3,8-diol oil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Impetigo1 trial

References

Drug Info

Quick Facts

Related News